The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Design, power, and interpretation of studies in the standard murine model of ALS
Abstract
Identification of SOD1 as the mutated protein in a significant subset of familial amyotrophic lateral sclerosis (FALS) cases has led to the generation of transgenic rodent models of autosomal dominant SOD1 FALS. Mice carrying 23 copies of the human SOD1(G93A) transgene are considered the standard model for FALS and ALS therapeutic studies. To date, there have been at least 50 publications describing therapeutic agents that extend the lifespan of this mouse. However, no therapeutic agent besides riluzole has shown corresponding clinical efficacy. We used computer modeling and statistical analysis of 5429 SOD1(G93A) mice from our efficacy studies to quantify the impact of several critical confounding biological variables that must be appreciated and should be controlled for when designing and interpreting efficacy studies. Having identified the most critical of these biological variables, we subsequently instituted parameters for optimal study design in the SOD1(G93A) mouse model. We retested several compounds reported in major animal studies (minocycline, creatine, celecoxib, sodium phenylbutyrate, ceftriaxone, WHI-P131, thalidomide, and riluzole) using this optimal study design and found no survival benefit in the SOD1(G93A) mouse for any compounds (including riluzole) administered by their previously reported routes and doses. The presence of these uncontrolled confounding variables in the screening system, and the failure of these several drugs to demonstrate efficacy in adequately designed and powered repeat studies, leads us to conclude that the majority of published effects are most likely measurements of noise in the distribution of survival means as opposed to actual drug effect. We recommend a minimum study design for this mouse model to best address and manage this inherent noise and to facilitate more significant and reproducible results among all laboratories employing the SOD1(G93A) mouse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inappropriate data cleaning has the potential to bias study outcomes [53]; providing the reasoning for removing data points enables the distinction to be made between responsible data cleaning and data manipulation.”
From Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0 (2020) · cites this paper as [53]
In the citing paper
“The ALS Therapy Development Institute rigorously retested more than 100 drug candidates in the superoxide dismutase 1 (SOD1) mouse model, and they were unable to replicate many of the previously reported preclinical efficacy findings85.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [85]
In the citing paper
“Lack of reproducibility in preclinical models and lack of translation from preclinical efficacy for drugs tested in the SOD1 mouse model to patients with ALS explain why the profiling of drug candidates in the SOD1 mouse model poorly translated into clinical efficacy85.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [85]
In the citing paper
“The reproducibility of preclinical results has been problematic in the field of amyotrophic lateral sclerosis (ALS).”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [85]
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Sterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V. O., Li, M., Sarang, S. S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,069
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., & Hall, E. D. (1996) · Annals of Neurology · doi:10.1002/ana.410390203 · Cited by 647
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2019) · CHANCE · doi:10.1080/09332480.2019.1579573 · Cited by 474
Tu, P., Raju, P., Robinson, K. A., Gurney, M. E., Trojanowski, J. Q., & Lee, V. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.3155 · Cited by 415
Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
Križ, J., Nguyen, M. D., & Julien, J. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0487 · Cited by 411
Ryu, H., Smith, K., Camelo, S. I., Carreras, I., Lee, J., Iglesias, A. H., Dangond, F., Cormier, K. A., Cudkowicz, M. E., H. Brown, R., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03077.x · Cited by 353
Chiu, A. Y., Zhai, P., Canto, M. C. D., Peters, T. M., Kwon, Y. W., Prattis, S. M., & Gurney, M. E. (1995) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1995.1027 · Cited by 326
Drachman, D. B., Frank, K., Dykes‐Hoberg, M., Teismann, P., Almer, G., Przedborski, S., & Rothstein, J. D. (2002) · Annals of Neurology · doi:10.1002/ana.10374 · Cited by 307
Minocycline delays disease onset and mortality in a transgenic model of ALS
Bosch, L. V. D., Tilkin, P., Lemmens, G., & Robberecht, W. (2002) · Neuroreport · doi:10.1097/00001756-200206120-00018 · Cited by 297
Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS
Heiman-Patterson, T. D., Deitch, J. S., Blankenhorn, E. P., Erwin, K. L., Perreault, M. J., Alexander, B. K., Byers, N., Toman, I., & Alexander, G. M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.02.006 · Cited by 236
Klivènyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02160.x · Cited by 201
The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies
Gurney, M. E. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00247-5 · Cited by 189
Canto, M. C. D., & Gurney, M. E. (1997) · Acta Neuropathologica · doi:10.1007/s004010050650 · Cited by 188
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS
Zhang, W., Narayanan, M. V., & Friedlander, R. M. (2003) · Annals of Neurology · doi:10.1002/ana.10476 · Cited by 185
Kiaei, M., Petri, S., Kipiani, K., Gardian, G., Choi, D., Chen, J., Calingasan, N. Y., Schafer, P. H., Muller, G. W., Stewart, C. A., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5253-05.2006 · Cited by 183
Acsádi, G., Anguelov, R. A., Yang, H., Tóth, G., Thomas, R., Jáni, Á., Wang, Y., Ianakova, E., Mohammad, S., Lewis, R. A., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402753812458 · Cited by 180
Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis
Gurney, M. E., Fleck, T. J., Himes, C. S., & Hall, E. D. (1998) · Neurology · doi:10.1212/wnl.50.1.62 · Cited by 178
Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS
Alexander, G. M., Erwin, K. L., Byers, N., Deitch, J. S., Augelli, B. J., Blankenhorn, E. P., & Heiman-Patterson, T. D. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.07.002 · Cited by 176
Genistein Is Neuroprotective in Murine Models of Familial Amyotrophic Lateral Sclerosis and Stroke
Trieu, V. N., & Uckun, F. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0577 · Cited by 149
Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis)
Ende, N., Weinstein, F., Chen, R., & Ende, M. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00602-0 · Cited by 137
Manganese porphyrin given at symptom onset markedly extends survival of ALS mice
Crow, J. P., Calingasan, N. Y., Chen, J., Hill, J. L., & Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20552 · Cited by 136
Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Ferrante, K. L., Bogdanov, M. B., Kaddurah-Daouk, R. F., & Beal, M. F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00188.x · Cited by 123
Derave, W., Bosch, L. V. D., Lemmens, G., Eijnde, B. O., Robberecht, W., & Hespel, P. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00041-x · Cited by 116
Optimal methods to characterize the G93A mouse model of ALS
Mena, F. J. M., Muñoz, M. J., Yagüe, G., Mendez, M. F., Moreno, M., Ciriza, J., Zaragoza, P., & Osta, R. (2005) · Amyotrophic Lateral Sclerosis · doi:10.1080/14660820510026162 · Cited by 107
Chen, R., & Ende, N. (2000) · PubMed · Cited by 99
Snow, R. J., Turnbull, J., da Silva, S., Jiang, F., & Tarnopolsky, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00212-4 · Cited by 62
Amyotrophic lateral sclerosis: recent advances and future therapies
Nirmalananthan, N., & Greensmith, L. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000187248.21103.c5 · Cited by 60
Andries, M., Damme, P. V., Robberecht, W., & Bosch, L. V. D. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.018 · Cited by 58
Trieu, V. N., Liu, R., Liu, X., & Uckun, F. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1905 · Cited by 44
Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses
Schiffer, D., & Fiano, V. (2004) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820310016822 · Cited by 41
Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity
Cudkowicz, M., Pastusza, K. A., Sapp, P. C., Mathews, R., Leahy, J. M., Pasinelli, P., Francis, J. W., Jiang, D., Andersen, J. K., & Brown, R. H. (2002) · Neurology · doi:10.1212/wnl.59.5.729 · Cited by 31
Preclinical studies: how much can we rely on?
Rothstein, J. D. (2004) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/17434470410020012 · Cited by 7
Chemotherapy Delays Progression of Motor Neuron Disease in the SOD1 G93A Transgenic Mouse
Bruce, K., Narayan, K., Kong, H. C., Larmour, I., Lopes, E. C., Turner, B. J., Bertram, J. F., & Cheema, S. S. (2004) · Chemotherapy · doi:10.1159/000077888 · Cited by 6
Research works printed but not linked: 3
- Chen R., 2000, J Med, 31, 21
- Andries M., 2006, Neurobiol Dis.
- Ramesh T. M., Buradagunta S., Thompson K., et al. Analysis of critical parameters for preclinical drug screening in the SOD1 G93A mouse model for amyotrophic lateral sclerosis., Abstract at the 13 th International Symposium on ALS/MND; November, 2002; Melbourne
Cited by
Sorted by citations
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000410 · Cited by 5,939
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
du Sert, N. P., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · Experimental Physiology · doi:10.1113/ep088870 · Cited by 3,547
Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0
Percie du Sert, N., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000411 · Cited by 2,677
“Inappropriate data cleaning has the potential to bias study outcomes [53]; providing the reasoning for removing data points enables the distinction to be made between responsible data cleaning and data manipulation.”
BackgroundThe ARRIVE guidelines 2.0: Updated guidelines for reporting animal research*
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20943823 · Cited by 1,443
Can Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354
Metadata
- Authors
- Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., Ramasubbu, J., & Heywood, J. A.
- Affiliations
- Amyotrophic Lateral Sclerosis Therapy Development Institute (US)
- University of California, San Francisco (US)
- Corresponding author
- Scott, Sean
- Venue
- Amyotrophic Lateral Sclerosis
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 9
- Issue
- 1
- Pages
- 4-15
- ISSN
- 1471-180X (ISSN-L)
- 1748-2968
- OpenAlex
- W2087656730
- Cited by
- 504
- References
- 40
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 20 · 2023: 11 · 2022: 21 · 2021: 22 · 2020: 33 · 2019: 30 · 2018: 27 · 2017: 34 · 2016: 37 · 2015: 40 · 2014: 47 · 2013: 35 · 2012: 30
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Amyotrophic Lateral Sclerosis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- SOD1 G93A mice, familial ALS, research design, statistical power, confounding variables, survival analysis, drug efficacy, riluzole, minocycline, ceftriaxone, thalidomide, celecoxib, 4-phenylbutyric acid, creatine, statistical noise, reproducibility
- MeSH terms
- Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Female, Male, Mice, Transgenic, Research Design, Species Specificity, Superoxide Dismutase, Survival Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
